Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canagliflozin in T1DM After Insulin Pump Interruption
NCT02673138Completed
- Sponsor
- Yale University
- Start
- Jan 2016
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of canagliflozin in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Yale University. Primary endpoints: Plasma Glucose Levels at 20 hours and Beta-hydroxybutyrate Levels at 20 hours. Started Jan 2016; status: completed.
02
Drugs
canagliflozin
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT02673138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02673138.